News

August 17, 2017September 8, 2017

Opdivo and Yervoy Combo Seen to Outperform Sutent in Untreated Advanced Kidney Cancer, But More Data Needed

News

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) was more effective in fighting advanced kidney cancer in previously untreated patients than the approved therapy Sutent (sunitinib), Bristol-Myers Squibb reported after analyzing data ... Read more

August 16, 2017August 16, 2017

Brain Cancer Vaccine SurVaxM Receives FDA Orphan Drug Status

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SurVaxM, an immunotherapy treatment developed at the Roswell Park Cancer Institute for a type of brain cancer called glioblastoma. SurVaxM, ... Read more

August 14, 2017August 14, 2017

New Immuno-Oncology Therapy Against Advanced Solid Tumors to Enter Phase 1 Clinical Studies

News

An experimental immuno-oncology treatment will move into early phase clinical trials for patients with advanced solid tumors, under a collaboration agreement between Cancer Research UK and Biotecnol. The therapy, called Tb535H, is a T-cell engager and ... Read more

August 10, 2017

Dozens of New Genes with Resistance to Cancer Immunotherapy Discovered

News

Researchers have identified dozens of new genes associated with resistance to anti-cancer immunotherapies, shedding light on ways to overcome such resistance. The study, “Identification of essential genes for cancer immunotherapy,” ... Read more

August 4, 2017

FDA Approves Opdivo for Two Metastatic Colorectal Cancers That Failed to Respond to Chemo

News

The U.S. Food and Drug Administration has approved the immunotherapy Opdivo (nivolumab) as a treatment for two colorectal cancers that failed to respond to a chemotherapy combination, according to its developer, Bristol-Myers Squibb. Opdivo becomes ... Read more

August 3, 2017

FDA Grants Breakthrough Therapy Status to Imfinzi for Unresectable NSCLC

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Imfinzi (durvalumab) for patients with locally advanced, unresectable (unable to be removed with surgery) non-small cell lung cancer (NSCLC), ... Read more

August 1, 2017

Natural Killer Cells Are Important to Ceplene’s Ability to Keep Leukemia in Remission, Trial Shows

News

An immune system component known as natural killer cells is crucial for a combination of Ceplene and interleukin-2 to keep acute myeloid leukemia in remission, according to a Phase 4 clinical trial. ... Read more

July 22, 2017July 23, 2017

COX-2 Inhibitors May Improve Cancer Immunotherapy Response

News

A new study shows that tumors that constantly express the protein IDO1 (indoleamine 2,3-dioxygenase) are sensitive to COX-2 inhibitors, which may provide an increase in T-cell anti-tumor function. The study ... Read more

July 21, 2017July 21, 2017

Opdivo, Yervoy, and Keytruda May Induce Rare Adverse Reactions Affecting the Eye, FDA Says

News

The U.S. Food and Drug Administration (FDA) is considering adding the risk of eye toxicities that could cause vision loss and retinal detachment on the labels of Bristol-Myers Squibb’s Opdivo (nivolumab) ... Read more

July 20, 2017

NT-219 Re-sensitizes Cancer to Keytruda, Stopping Tumor Progression, Study Shows

News

Adding TyrNovo‘s NT-219 to Merck’s Keytruda (pembrolizumab) converted Keytruda-resistant tumors into therapy responders, stopping tumor progression, a study reports. The research, which involved a number of cancers, was a collaboration between Bar Ilan University and Rabin ... Read more